Advertisement

Lymphocyte Subpopulations in Melanoma Patients Treated with Dendritic Cell Vaccines

  • Zaira G. Kadagidze
  • Anna A. Borunova
  • Tatiana N. Zabotina
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 601)

Abstract

The main goal of cancer immunotherapy is to induce or boost tumor-specific effector cells able to eliminate or reduce tumor progression. In this study, we characterized lymphocyte phenotypes in melanoma patients receiving dendritic cell (DC)-based vaccinotherapy. We found that several biological markers served as unfavorable prognostic factors for patients’ response to therapy. This included decrease of CD4+ and CD8+ lymphocyte levels, 10% and higher increase of CD16+CD3+CD8+ lymphocyte population, and increase of CD16+CD8+perforin+T lymphocytes, especially in combination with decreased levels of CD16+CD8-perforin+ and CD8+CD16-perforin+ cells. Increase in CD8+CD16-perforin+ T lymphocytes with normal levels of CD16+CD8-perforin+ cells and the absence of CD16+CD8+perforin+ and regulatory lymphocytes were shown to be the positive prognostic markers for patients’ response to DC vaccines.

Keywords

Dendritic Cell Natural Killer Cell Melanoma Patient Lymphocyte Subpopulation Dendritic Cell Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Groscurth, P. and Filgueira, L. (1998) Killing mechanisms of cytotoxic T lymphocytes. News Physiol. Sci. 13, 17–21.PubMedGoogle Scholar
  2. Kadagidze, Z.G., Chertkova, A.I. and Slavina, E.G. (2006) Immunoregulatory CD25+CD4+ cells. Russ. Biother. J., 7, 13–21.Google Scholar
  3. Kim, K.D., Kim, J.K., Kim, S.J., Choe, I.S., Chung, T.H., Choe, Y.K. and Lim, J.S. (1999) Protective antitumor activity through dendritic cell immunization is mediated by NK cell as well as CTL activation. Arch. Pharm. Res. 22, 340–347.CrossRefPubMedGoogle Scholar
  4. Smyth, M.J., Thia, K.Y., Street, S.E., Cretney, E., Trapani, J.A., Taniguchi, M., Kawano, T., Pelikan, S.B., Crowe, N.Y. and Godfrey, D.I. (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661–668.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Zaira G. Kadagidze
    • 1
  • Anna A. Borunova
    • 1
  • Tatiana N. Zabotina
    • 1
  1. 1.N.N. Blokhin Russian Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations